MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management

Figure 3

Heterotopic patient-derived xenografted mice injected with ⁶⁸Ga-DOTA-AF7p-1. (a) PET/CT image of representative heterotopic PDX mouse injected with ⁶⁸Ga-DOTA-AF7p-1 acquired 90 min after injection. Tumour locations are indicated by white arrows. (b) Immunohistochemistry of tumour tissue from PDX mice. MT1-MMP was detected using LEM2/15 antibody. Scale bar: 1000 µm. Higher magnification of the boxed area is shown at the right corner. Scale bar: 50 µm. (c) Tumour volume was measured by CT four times after onset of PET imaging study. Each tumour is represented by a different colour line on the graph. (d) Tumour uptake (quantified by PET imaging and expressed as %ID/g) as a function of tumour volume for all scanned mice, showing that there is no relationship between tumour size and ⁶⁸Ga-DOTA-AF7p-1 uptake. (e) Variation of tumour uptake of ⁶⁸Ga-DOTA-AF7p-1 along the PET imaging study. (f) Variation of kidneys and liver uptakes of ⁶⁸Ga-DOTA-AF7p-1 along the PET imaging study.

(a)

(b)

(c)

(d)

(e)

(f)